Tiziana Life Sciences
  • Our Company
    • Our Company
    • About us
    • Our Team
  • Technology
  • Pipeline
    • Intranasal Foralumab
      • Secondary Progressive Multiple Sclerosis
      • Alzheimer’s Disease
      • Other Indications
    • Anti IL-6R (TZLS-501)
    • Milciclib (TZLS-201)
  • Investors, News & Media
    • News
    • Media
    • Publications
    • Investors
  • Contact
Select Page
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

by Paul | 1 November 2024 | News

NEW YORK, November 1, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Recent Posts

  • Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
  • Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
  • Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
  • Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
  • Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Recent Comments

No comments to show.

Tiziana Life Sciences, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda  |  info@tizianalifesciences.com   |  +44 (0) 207 495 2379

  • Follow
  • Follow

© Tiziana Life Sciences 2025  |   Legal  |  Privacy Policy

NASDAQ: TLSA